FIELD: antibodies.
SUBSTANCE: present invention relates to a stable liquid preparation of the antibody tocilizumab in a double buffered phosphate-amino acid system. An antibody included in a phosphate-amino acid-based double buffer system acquires optimal stability at both low and high concentrations. In addition, the formulation of the antibody incorporated in the phosphate-amino acid double buffer system has a low viscosity and is suitable for therapeutic administration of high concentrations of the antibody.
EFFECT: invention is suitable for therapeutic administration of high concentrations of the antibody.
9 cl, 4 dwg, 21 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| STABLE PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2736830C2 |
| ANTIBODY COMPOSITIONS | 2010 |
|
RU2548772C2 |
| STABLE BINDING PREPARATIONS BASED ON IgG4 | 2013 |
|
RU2644214C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES TO C5 | 2018 |
|
RU2787595C2 |
| STABLE LIQUID PREPARATION OF ANTIBODY | 2009 |
|
RU2518278C2 |
| IMMUNOGLOBULIN COMPOSITIONS AND PRODUCTION PROCEDURE | 2004 |
|
RU2358763C2 |
| FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES | 2013 |
|
RU2683861C2 |
| COMPOSITIONS BASED ON BISPECIFIC ANTIBODIES TO IL-4/IL-13 | 2014 |
|
RU2690850C2 |
| CONCENTRATED PROTEIN PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATION | 2011 |
|
RU2626512C2 |
| STABLE AQUEOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY COMPOSITION | 2016 |
|
RU2699544C2 |
